[Corneal collagen crosslinking with riboflavin for keratoconus patients]

Menga Mengarelli C, Pichon-Riviere A, Augustovski F, García Martí S, Alcaraz A, Bardach A, Ciapponi A, López A, Rey-Ares L
Record ID 32015001159
Authors' objectives: To assess the available evidence on the efficacy, safety and coverage related aspects regarding the use of corneal collagen crosslinking with riboflavin in patients with keratoconus. Keratoconus is a disorder characterized by a progressive and bilateral increase in the corneal curvature with apical thinning, resulting in irregular corneal astigmatism. Its etiology is unknown. It affects children and young individuals; it stabilized after 30 years old. In the general population, its reported frequency is 1/2,000 individuals. Rigid contact lenses, rings or corneal transplantation may be used for therapy Crosslinking with riboflavin (CXL) is proposed as a treatment alternative for mild to moderate keratoconus, alone or as a supplement to other treatments. Crosslinking involves applying a photosensitive product (such as riboflavin) to the cornea and then activate it using type A ultraviolet rays to increase corneal rigidity by creating collagen bridges and thus stopping keratoconus progression.
Authors' recommendations: Low quality evidence is non-conclusive regarding the benefits corneal collagen crosslinking with riboflavin could provide keratoconus patients. Some studies suggest it could slightly improve visual acuity. Some clinical practice guidelines mention this is a treatment option for young people who do not tolerate lenses. Several health sponsors surveyed do not cover it because they consider it experimental and with no proven efficacy.
Project Status: Completed
Year Published: 2015
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Humans
  • Collagen
  • Cornea
  • Keratoconus
  • Riboflavin
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.